ClinicalTrials.gg
Status unknownNCT00011895Updated Jun 24, 2005

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

A Phase 4 interventional study of Abacavir sulfate, Lamivudine and Zidovudine and Efavirenz in HIV Infections, sponsored by GlaxoSmithKline. Status unknown at 42 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2002), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.

Enrollment
8th of 50
400 · median 78
Started
2001
the only one that year
Phase 4
13 of 57
none open now
Registered
32nd of 57
by date
Lead sponsor
5 of 57
GlaxoSmithKline

Among the 57 studies testing abacavir in HIV Infections, this one is the 8th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2001, is one of 13 in phase 4, and was the 32nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:

About abacavir

Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing abacavir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).

Read the detailed description

Patients receive TZV plus EFV in the 48-week Induction Phase. Eligible patients, defined as those with plasma HIV-1 RNA under 50 copies/ml, participate in the 48-week Maintenance Phase. Patients are randomized equally to receive either TZV plus EFV or TZV alone.

An immunology substudy will be conducted, including approximately the first 100 patients enrolled who agree to participate.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Zidovudine
  • Lamivudine
  • Drug Combinations
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • abacavir
  • efavirenz
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 13 years old.
  • Are -positive.
  • Have a viral load of at least 5,000 copies/ml.
  • Agree to use adequate and reliable methods of . Note: Hormonal birth control is not considered adequate.
  • Provide written consent of a parent or guardian, if under 18 years of age.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have taken nonnucleoside reverse transcriptase inhibitors.
  • Have taken other anti- drugs for 2 weeks or more.
  • Have an opportunistic (AIDS-related) infection.
  • Are pregnant or breast-feeding.
  • Have had hepatitis within the past 6 months.
  • Are allergic to the study drugs or their ingredients.
  • Have a mental, physical, or substance abuse disorder.
  • Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease.
  • Have a gastrointestinal disorder that affects drug absorption or makes it difficult to take medication by mouth.
  • Have received within 4 weeks before study entry, or may require during the study period, radiation therapy, chemotherapy, or drugs that affect the immune system (such as drugs, interleukins, vaccines, or interferons).
  • Have received an HIV vaccine within 3 months before study entry, or are scheduled to receive one during the study period.
  • Require foscarnet or other drugs that are shown to be effective against HIV.
  • Are taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives.
  • Are taking experimental drugs.
  • Are unlikely to complete the study or take the drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Enrollment
400 participants

Interventions

06

Study locations

42 sites
  • Phoenix Body Positive
    Phoenix, Arizona 85006, United States
  • Health for Life Clinic
    Little Rock, Arkansas 72205, United States
  • Orange County Ctr for Special Immunology
    Fountain Valley, California 92708, United States
  • Pacific Horizons Med Group
    San Francisco, California 94115, United States
  • Beacon Clinic / Boulder Community Hosp
    Boulder, Colorado 80304, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • Infectious Disease Consultants
    Altamonte Springs, Florida 32701, United States
  • North Broward Hosp District / HIV Clinical Research
    Fort Lauderdale, Florida 33311, United States
  • SBMA Research
    Miami Beach, Florida 33140, United States
  • Univ of Miami / Jackson Memorial Hosp
    Miami, Florida 33136, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Cook County Gen Hosp / Division of Infect Diseases
    Chicago, Illinois 60612, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • University of Louisville / ID Division
    Louisville, Kentucky 40202, United States
  • HIV Outpatient Clinics / LA State Univ Med Ctr
    New Orleans, Louisiana 70112, United States
  • Boston Med Ctr
    Boston, Massachusetts 02118, United States
  • Dr Paul Benson
    Berkley, Michigan 48072, United States
  • Hennepin County Med Ctr
    Minneapolis, Minnesota 55415, United States
  • Regions Hosp / HIV/AIDS Program
    St. Paul, Minnesota 55101, United States
  • CRC of Mississippi
    Jackson, Mississippi 39202, United States
  • Wellness Ctr / Las Vegas
    Las Vegas, Nevada 89102, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • NJCRI
    Newark, New Jersey 07103, United States
  • SUNY / Health Sciences Ctr at Brooklyn
    Brooklyn, New York 11203, United States
  • Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ
    New York, New York 10021, United States
  • ID Consultants
    Charlotte, North Carolina 28203, United States
  • East Carolina Univ School of Medicine
    Greenville, North Carolina 27858, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • Univ of Oklahoma Infectious Disease Institute
    Oklahoma City, Oklahoma 73117, United States
  • Associates in Med and Mental Health
    Tulsa, Oklahoma 74114, United States
  • Univ of Tennessee Med Ctr at Knoxville
    Knoxville, Tennessee 37920, United States
  • Texas Tech Health Sciences Ctr
    El Paso, Texas 79905, United States
  • AIDS Outreach Center
    Fort Worth, Texas 76104, United States
  • Metroplex Infectious Disease
    Fort Worth, Texas 76104, United States
  • Tarrant County Infectious Diseases Associates
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts
    Houston, Texas 77004, United States
  • Diversified Med Practices, PA
    Houston, Texas 77027, United States
  • Infectious Diseases Associates of Houston
    Houston, Texas 77030, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22003, United States
  • Infectious Disease Consultants
    Fairfax, Virginia 22030, United States
  • Swedish Med Ctr
    Seattle, Washington 98122, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00011895
Lead sponsor
GlaxoSmithKline
First posted
Aug 31, 2001
Start date
Feb 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abacavir · Lamivudine · Zidovudine · Efavirenz

Start the discussion